Disclosed herein is a composition comprising a biofilm degrading protease, a disulphide bond breaking agent and an antibiotic, as well as a method for debriding biofilm (e.g. on an implant) in a patient's body. The method comprises contacting the biofilm with a combination of a biofilm degrading protease and disulphide bond breaking agent.

Compositions comprising an engineered or non-naturally occurring polypeptides comprising two or more domains selected from Sulfide quinone oxidoreductase, Thiosulfate Sulfurtransferase and persulfide dioxygenase, and a phosphate binding motif are provided along with methods of detoxifying bacterial endotoxins and H.sub.2S with such compositions.

Compositions comprising an engineered or non-naturally occurring polypeptides comprising two or more domains selected from Sulfide quinone oxidoreductase, Thiosulfate Sulfurtransferase and persulfide dioxygenase, and a phosphate binding motif are provided along with methods of detoxifying bacterial endotoxins and H.sub.2S with such compositions.

Provided are methods of making and using an antimicrobial composition, optionally including adding one or more enzymes to a suspension of lees, wherein the lees was formed by fermenting fruit with yeast and the one or more optional enzymes comprise a protease, a carbohydrase, or a combination of a protease and a carbohydrase; and forming a dried lees by drying the lees. In some examples the fruit includes chardonnay grapes, pinot noir grapes, cabernet franc grapes, or a combination of any two or more of chardonnay grapes, pinot noir grapes, and cabernet franc grapes; the yeast includes one or more Saccharomyces cerevisiae strains of yeast; and drying the lees by heating it. In some examples, trub made from fermenting a grain such as barley is used instead of lees. An antimicrobial composition made as provided may be administered to an animal to inhibit bacterial growth.

Provided are methods of making and using an antimicrobial composition, optionally including adding one or more enzymes to a suspension of lees, wherein the lees was formed by fermenting fruit with yeast and the one or more optional enzymes comprise a protease, a carbohydrase, or a combination of a protease and a carbohydrase; and forming a dried lees by drying the lees. In some examples the fruit includes chardonnay grapes, pinot noir grapes, cabernet franc grapes, or a combination of any two or more of chardonnay grapes, pinot noir grapes, and cabernet franc grapes; the yeast includes one or more Saccharomyces cerevisiae strains of yeast; and drying the lees by heating it. In some examples, trub made from fermenting a grain such as barley is used instead of lees. An antimicrobial composition made as provided may be administered to an animal to inhibit bacterial growth.

Combined multistage microbial preparations for enhancement of the biological skin barrier and maintenance of healthy skin microbiota are disclosed. The preparations are useful in chronic problems associated with dysbiosis such as atopic dermatitis, acne, rosacea and vitiligo or acute problems caused by damage of the skin such as burns, cuts and contusions.

The invention relates to a pharmaceutical composition of the cores of microgranules containing pancreatin, cetyl alcohol, poloxamer 407 in predetermined quantities, the production method, as well as the production of the water-based enteric-coated microgranules. Furthermore, the resulting oral dosage form does not contain residual acetone. The technical result is in achieving higher stability of the cores and the enteric-coated microgranules, respectively, while maintaining the good solubility of the enteric-coated microgranules, which allows the application of the claimed pancreatin microgranules for the preparation of safe and non-toxic drugs for the treatment of digestive disorders.

The invention relates to a pharmaceutical composition of the cores of microgranules containing pancreatin, cetyl alcohol, poloxamer 407 in predetermined quantities, the production method, as well as the production of the water-based enteric-coated microgranules. Furthermore, the resulting oral dosage form does not contain residual acetone. The technical result is in achieving higher stability of the cores and the enteric-coated microgranules, respectively, while maintaining the good solubility of the enteric-coated microgranules, which allows the application of the claimed pancreatin microgranules for the preparation of safe and non-toxic drugs for the treatment of digestive disorders.

Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.

Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.